Financial Statements
AC Immune SA (ACIU)
$2.96
-0.07 (-2.31%)
Year | XLSX 2023 | XLSX 2022 | XLSX 2021 | XLSX 2020 | XLSX 2019 |
---|---|---|---|---|---|
Total assets | 182,814 | 185,938 | 261,443 | 238,740 | 299,250 |
Total Current Assets | 125,153 | 128,094 | 202,634 | 231,767 | 292,774 |
Cash and Short Term Investments | 103,048 | 122,586 | 198,216 | 225,893 | 288,587 |
Cash and cash equivalents | 78,494 | 31,586 | 82,216 | 160,893 | 193,587 |
Short Term Investments | 24,554 | 91,000 | 116,000 | 65,000 | 95,000 |
Receivables | 15,668 | 800 | 1,403 | 1,920 | 1,399 |
Inventory | - | 0 | -1,403 | -1,920 | -1,399 |
Other Current Assets | - | 4,708 | 4,418 | 5,874 | 4,187 |
Total non-current Assets | 57,661 | 57,844 | 58,809 | 6,973 | 6,476 |
Property, Plant & Equipment Net | 6,884 | 7,067 | 8,030 | 6,639 | 6,172 |
Goodwill and Intangible Assets | 50,416 | 50,416 | 50,416 | - | - |
Goodwill | 50,416 | 50,416 | 50,416 | - | - |
Intangible Assets | 50,416 | 50,416 | 50,416 | - | - |
Long Term Investments | 361 | 361 | 363 | 334 | 304 |
Other non-current Assets | - | 361 | 363 | - | - |
Total liabilities | 22,171 | 16,947 | 29,464 | 23,262 | 26,808 |
Total current liabilities | 13,576 | 11,481 | 20,026 | 14,018 | 17,510 |
Payables | 1,679 | 929 | 2,003 | 2,184 | 142 |
Short Term debt | 672 | 548 | 570 | 443 | 1,094 |
Deferred revenue | 138 | 587 | 717 | 306 | 4,477 |
Other Current Liabilities | 11,087 | 9,417 | 16,736 | 11,085 | 11,797 |
Total non-current liabilities | 8,595 | 5,466 | 9,438 | 9,244 | 9,298 |
Long Term debt | 2,825 | 2,253 | 2,340 | 1,780 | 1,813 |
Other non-current Liabilities | 5,770 | 3,213 | 7,098 | 7,464 | 7,485 |
Total shareholders equity | 160,643 | 168,991 | 231,979 | 215,478 | 272,442 |
Common Stock | 2,089 | 1,797 | 1,794 | 1,538 | 1,437 |
Retained earnings | -316,197 | -264,015 | -200,942 | -132,850 | -75,521 |
Accumulated Other Comprehensive Income Loss | -51 | 10 | - | - | - |
Other Stockholders Equity | 474,802 | 431,199 | 431,127 | 346,790 | 346,526 |
Total debt | 3,497 | 2,801 | 2,910 | 2,223 | 2,907 |
Total Investments | 24,915 | 91,361 | 116,363 | 65,000 | 95,304 |
Net Debt | -74,997 | -28,785 | -79,306 | -158,670 | -190,680 |
AC Immune SA income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes AC Immune SA FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.